
Living With a New RAS-Targeted Drug for Pancreatic Cancer
Key Takeaways
- FDA approval established daraxonrasib as the first direct RAS-targeting oral therapy for metastatic PDAC after ≥1 systemic treatment or when combination chemotherapy is not feasible.
- Phase 3 data showed improved median OS (13.2 vs 6.7 months) and disease control (7.2 vs 3.6 months) versus chemotherapy, alongside better pain and QoL trajectories.
Rasonque (daraxonrasib), the first approved drug to directly target RAS in pancreatic cancer, nearly doubled survival in a key trial. Two patients, a caregiver and the professionals who care for people like them explain what it means to live with the disease.
Brad Dugai thought he had pulled a muscle at the gym.
It was spring 2024, and his life on the small Chesapeake Bay island in Virginia was full: a wife, three grown children, trips abroad, a full-time job, workouts three or four times a week and plenty of time on the water. The pressure in his abdomen and pain in his back didn't ease, but blood work results came back normal. So, two nights before he and his wife were set to fly to Los Angeles for their son's 21st birthday, Dugai decided to go to the emergency room, just to be safe.
The physician on duty read the CT scan himself. "I can't definitively diagnose it from the CT, but I think you have pancreatic cancer," Dugai recalled him saying.
"I knew I had a pancreas. We all do," says Dugai, who was 53 at the time. "But in that moment, I became very aware that I had a pancreas, and that I had a problem with my pancreas."
A biopsy confirmed Stage 3 pancreatic ductal adenocarcinoma. Over the next year, Dugai went through two chemotherapy regimens and MRI-guided radiation that destroyed the tumor in his pancreas. About eight months later, the cancer came back in a nearby lymph node, and he was restaged with Stage 4 disease. His oncologist told him he needed a clinical trial.
By the time he enrolled in a study of Rasonque (daraxonrasib) at Duke Health in Durham, North Carolina, the lymph node "had grown to the size of a large plum and was pressing on nerves running down my left leg," he says. He was walking with a limp and couldn't stay on his feet for long.
He took his first dose on Sept. 12, 2025. "Within 24 hours, all of that pain and the limp were 100% gone," he says.
A drug for a target once called ‘undruggable’
On Aug. 26, 2026, the Food and Drug Administration (FDA) approved Rasonque, a pill for adults with metastatic pancreatic adenocarcinoma who have already received at least one systemic treatment, such as chemotherapy or who can't receive combination chemotherapy. It is the first approved drug designed to directly target RAS in pancreatic cancer.
RAS is a family of proteins that act like a switch for cell growth. In most pancreatic cancers, a mutation leaves that switch stuck in the "on" position. For decades, researchers considered RAS “undruggable.” Rasonque works by teaming up with a protein inside the cell, and the pair then clamps onto active RAS and blocks its growth signal.
Christopher Graham, a clinical research nurse in the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute in Boston who has cared for patients with pancreatic cancer for more than 12 years, explains it to patients with everyday comparisons, such as "turning off a light switch or the gas pedal is stuck. We're trying to interrupt a pathway that's causing the cancer to grow."
When Dugai joined the trial, the drug didn't even have a name, only a code: RMC-6236. "I knew nothing about it," he says. "Just knew that it was the clinical trial that seemed to fit my cancer mutation, so it was kind of like a last resort. Let's see what this does."
That first day changed his outlook. "It was at that point that my wife and I really knew, OK, there could be some real significant possibility for this," he says, "and it's just gotten better since."
What the research showed
The approval was based on a phase 3 trial called RASolute 302 (NCT06625320), which included 500 adults with metastatic pancreatic cancer who had been treated before.
People taking Rasonque lived a median of 13.2 months, compared with 6.7 months with chemotherapy. Their cancer was controlled for a median of 7.2 months, versus 3.6 months. Patients taking the drug also went longer before their pain worsened and before their overall quality of life declined, and fewer stopped treatment because of side effects.
Dugai has had no evidence of disease on his scans for about eight months. "I'm great today," he says.
Experts are careful not to overstate what the drug can do. "[Rasonque] is a remarkable drug, but it didn't cure people yet, right?" says Dr. Paul E. Oberstein, a gastrointestinal oncologist at NYU Langone's Perlmutter Cancer Center in New York. "It prolonged survival. It helped improve quality of life. But it did not yet result in cures."
Dugai understands that, too. "The reality of this is that Rasonque isn't a cure, and I think we all know that," he says. "But it's a significant game changer in terms of making the disease manageable and livable."
A different path to the same pill
Russell Reed and his wife, Marnie, knew pancreatic cancer long before it reached him. Marnie's father died of the disease in 2008, about six weeks after he was diagnosed.
In August 2024, while Russ was looking for a new job, a pain under his right rib cage wouldn't go away. He didn't wait to see his doctor, and an ultrasound found a tumor. He got the call on his way to a job interview.
"The fight was on. It was not a pity party," he says.
The cancer was Stage 2B, and the tumor had wrapped around his bile duct. At Memorial Cancer Institute in Hollywood, Florida, he had chemotherapy and radiation, then a Whipple procedure, a complex surgery to remove the tumor, in February 2025, followed by more chemotherapy. "In August of 2025, I had no evidence of disease," he says. "That was a real win at the time."
Four months later, the cancer had spread to his liver. More chemotherapy and a procedure to destroy one of the liver tumors followed, but the chemotherapy stopped working, and Russ was hospitalized in May and June 2026. His doctors pointed him to Rasonque, which he describes as the last tool in the toolbox.
Russ wasn't in a clinical trial. Before the FDA approved the drug, its maker, Revolution Medicines, made it available through the FDA's expanded access program, which allows some people with serious illnesses to receive drugs that aren't yet approved. He started Rasonque on July 3, 2026, and was the first patient at Memorial Cancer Institute to receive it this way.
Pain from the tumors in his liver had required oxycodone. "Within 12 days, the tumor pain was completely gone," he says.
"[It's] extending my life, and it's giving me not only quantity but quality as well," Russ says. When he and Marnie spoke with CURE, they had just returned from an 18-day trip to Europe.
Why tumor testing matters
Because the drug targets RAS, patients and their families should ask whether the tumor has had genomic testing, sometimes called next-generation sequencing or biomarker testing. At Dana-Farber, that testing is typically ordered at the first visit, according to Adrienne Kolk, a nurse practitioner in the Gastrointestinal Cancer Center. It may be repeated if the cancer grows "to make sure that they're still a KRAS or if they didn't have a KRAS initial[ly], to see if they've acquired one," she says.
Trading the infusion chair for a pill bottle
For Dugai, moving from chemotherapy to a daily pill was a relief. His first regimen "wreaked havoc on me mentally, physically and emotionally," he says. "It gave me this intense brain fog." His wife sometimes found him curled up on the floor, crying.
A pill taken at home brings its own responsibilities. Rasonque is taken once a day at the same time, with or without food. If a dose is more than four hours late, patients should skip it and take the next one on schedule; they should not take an extra dose after vomiting.
Kolk suggests setting a daily phone alarm as a reminder. "We usually instruct patients to take it in the evening to help avoid any sort of [gastrointestinal] upset." Dana-Farber's oral chemotherapy team also follows up by phone to check on how patients are doing with their doses, she adds.
Taking a pill at home doesn't mean being on your own. Early in treatment, Dugai was traveling to Duke every week; now he returns monthly for laboratory work.
The rash
The most common side effect of Rasonque is a skin rash, which affected 86% of patients in clinical trials. For Dugai, it was the hardest part.
"I would go to sleep at night, and I'd wake up in the morning, and my pillow would be covered with blood from the back of my head, from my face," he says. "My wife used to say it looked like a murder scene." The rash didn't hurt much, he says, "It felt like a pretty significant case of windburn or razor burn." But it covered his face, neck, chest and forearms with discolored, bleeding bumps.
Care teams now try to get ahead of the rash before the first dose. At Dana-Farber, patients typically start an oral antibiotic along with steroid creams before treatment begins, Kolk says, and the drug's prescribing information also recommends moisturizers and sunscreen. "We always tell people we'd rather overtreat than undertreat," Kolk says. Her team watches patients closely in the first weeks, "with a low threshold to get them involved in our dermatology department."
"Prophylaxis should be prescribed and reviewed with the patient before they even take that first dose," says Yolanda Justal, an advanced practice registered nurse at the University of Miami Sylvester Comprehensive Cancer Center. "We don't wait until after the rash develops."
For Dugai, a rash led to a cycle of pauses. Each time a rash reached Grade 3, a level of severity that requires stopping the drug, he paused treatment and took a course of steroids until the rash calmed down. Each time, the stretch he could stay on the drug got shorter. "By the time I had my last pause, it was 12 days that I could be on [it], which was just not sustainable," he says.
His Duke dermatologist, working closely with his oncology team, "cracked the code of the rash for me," he says. An oral medication called dapsone brought it under control, and Dugai has not had to pause treatment because of a rash in more than six months. Treatments that work for one person may not work for another, and patients should talk with their care team about the right approach for them.
Russ has dealt with the rash, too. “I'm not going to sugarcoat it. At times it's been pretty bad," he says. His scalp broke out badly until a prescription treatment cleared it. He has taken an antibiotic since his first day on Rasonque and uses a hydrocortisone cream on his face to keep the rash in check. Still, he says, "I'll take the rash over the alternative."
Because people taking Rasonque are advised to limit their time in the sun, Russ, who lives in South Florida, has put golf and gardening on the back burner. He hopes to pick them up again, with sun protection.
Other side effects to know about
Diarrhea affected 63% of patients in clinical trials and mouth sores affected 57%. Diarrhea often starts within the first few days, so many care teams send patients home with an antidiarrheal medication, such as loperamide, before the first dose. Rarer but serious problems include a hole in the bowel (in less than 1% of patients) and lung inflammation called pneumonitis (about 2%).
Justal tells patients to call right away for "any severe or worsening abdominal pain, pain that's accompanied with severe cramping, any blood in the stool or black tarry stools, or an inability to have a bowel movement or to pass gas." New or worsening cough or shortness of breath should also be reported quickly.
A pause is part of the plan
Many patients with pancreatic cancer fear that any break in treatment gives the cancer a chance to grow. Nurses say pauses and dose reductions are planned tools, not a sign that treatment has failed. In clinical trials, only 2.9% of patients stopped Rasonque permanently because of side effects.
"A lot of people are having their cancer respond really well, [so] they don't want to stop the pill even if side effects are bad," says Mary Helen Larsen, a clinical trials nurse at Memorial Sloan Kettering Cancer Center in New York.
"I explain to our patients that a treatment hold doesn't mean that the treatment isn't going to work," Justal says. "It's safer to hold the treatment than to force the patient to push through, because pushing through can lead to ultimately hospitalizations or permanent discontinuations."
When his rash flared, Russ took a 12-day break. His skin started to clear, but some of his tumor pain returned, so he restarted at a lower dose: 200 milligrams a day instead of 300. The rash is "not as bad, but it's still there," he says.
Cost, access and the next trials
With a market price of roughly $40,000 a month, cost is a real concern, though Kolk says most of her patients have not faced high copays. Pharmacy teams and manufacturer programs can help, and Justal recommends that financial navigation begin as soon as the decision is made to place the patient on Rasonque.
For the Reeds, the drug cost nothing while Russ received it through expanded access. Keeping it after approval took planning. Marnie, who says she is in touch with hundreds of patients and caregivers through an online community, had heard that at least one person's insurance company denied the drug because it wasn't yet in the insurer's system.
So she called the nurse navigator at their insurance company before the switch. "I said, ‘Look, this is what I've heard is happening. This is coming. We only have four weeks to get this done because he can't not have the drug,’" she says.
Russ was preapproved. But once Revolution Medicines set the price, their insurer denied coverage because of the cost. As Marnie puts it, "$40,000 a month is ridiculous, and nobody's going to pay that."
Rasonque is dispensed through specialty pharmacies, and the Reeds' pharmacy worked with their insurer and with the manufacturer's patient assistance program. "They're not going to let somebody not get the medicine because it's $40,000," Marnie says. "So, between the really great team at the pharmacy dispensing it, the insurance and the manufacturer, they're able to get it to a [reasonable] price point, which for us is $0."
There was no interruption in Russ' treatment, Marnie says, and the pharmacy even sent a care package of lotions and lip balm for dry skin. "There has been nothing that I've heard, and I'm really speaking to hundreds of people in this community on social, about anybody who's not getting it because of cost," she says.
Trials are already testing Rasonque earlier in treatment, including as a first treatment for metastatic disease and after surgery, as well as newer drugs aimed at specific RAS mutations. Graham says patients who have already received an approved RAS drug may not qualify for some of those newer trials, so it's worth asking about trial options early. Many trials now offer help with lodging and travel, he adds.
Back on the water
Rasonque hasn't given Dugai back everything. Chemotherapy left him with numbness in his hands, which makes typing difficult, and in his feet and some lingering brain fog. He has gone on short-term disability to focus on what matters most. A bout of sepsis and pneumonia after a flight during chemotherapy has made him wary of flying, and he and his wife have put international travel on hold. Driving trips to see his mother and sister in Florida are still on the calendar.
"I don't know when [Rasonque] could stop working for me," he says.
But this summer, for the first time since his diagnosis, Dugai was back on his boat. During chemotherapy, he says, "I had the concern that I couldn't responsibly captain the boat and ensure the safety of everybody on board in my condition. This year, I've been able to do that."
He's working in the yard again, too, even if he sometimes needs a nap afterward.
"Most days," he says, "I don't feel like I have cancer."
Related to this article








